These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2174822)

  • 41. Serum 90K/MAC-2BP glycoprotein levels in hepatocellular carcinoma and cirrhosis.
    Correale M; Giannuzzi V; Iacovazzi PA; Valenza MA; Lanzillotta S; Abbate I; Quaranta M; Caruso ML; Elba S; Manghisi OG
    Anticancer Res; 1999; 19(4C):3469-72. PubMed ID: 10629637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis of hepatocellular carcinoma in cirrhotic patients: a proof-of-concept study using serum micro-Raman spectroscopy.
    Taleb I; Thiéfin G; Gobinet C; Untereiner V; Bernard-Chabert B; Heurgué A; Truntzer C; Hillon P; Manfait M; Ducoroy P; Sockalingum GD
    Analyst; 2013 Jul; 138(14):4006-14. PubMed ID: 23608738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma.
    Kew MC; Berger EL
    Cancer; 1986 Jul; 58(1):127-30. PubMed ID: 2423221
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tissue polypeptide specific antigen as a marker used to determine the liver diseases.
    Paul D; Biswas R; Habib SH
    Kathmandu Univ Med J (KUMJ); 2011; 9(33):24-7. PubMed ID: 22610804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diaphragmatic cyst with elevated level of serum tissue polypeptide antigen.
    Ueda H; Andoh K; Kusano T; Iwasaki A; Inutsuka S
    Thorac Cardiovasc Surg; 1992 Aug; 40(4):195-7. PubMed ID: 1412392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Serum level of tissue polypeptide antigen and its mechanism of elevation in patients with benign liver diseases and hepatocellular carcinoma].
    Arashiyama Y; Watanabe F; Miyazaki H; Ogoshi H; Oizumi H
    Nihon Shokakibyo Gakkai Zasshi; 1984 Mar; 81(3):927. PubMed ID: 6086987
    [No Abstract]   [Full Text] [Related]  

  • 47. A clinical and laboratory evaluation of the behavior of tissue polypeptide antigen in liver cirrhosis.
    Collazos J; Genollá J; Ruibal A
    Digestion; 1992; 53(3-4):157-61. PubMed ID: 1291404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tissue polypeptide antigen--a marker antigen differentiating cholangiolar tumors from other hepatic tumors.
    Pastolero GC; Wakabayashi T; Oka T; Mori S
    Am J Clin Pathol; 1987 Feb; 87(2):168-73. PubMed ID: 3028121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Tissue polypeptide antigen (TPA) in liver tissue from patients with hepatocellular carcinoma].
    Onji M; Danjo K; Miyaoka H; Taniguchi Y; Ohta Y
    Nihon Shokakibyo Gakkai Zasshi; 1987 Nov; 84(11):2537-41. PubMed ID: 2831415
    [No Abstract]   [Full Text] [Related]  

  • 50. [Tissue polypeptide antigen].
    Sugiyama Y; Fukuda N; Mushiake H
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():750-2. PubMed ID: 20960863
    [No Abstract]   [Full Text] [Related]  

  • 51. Incidentally detected hepatocellular carcinoma in cirrhotic children.
    Bhatia V; Seth S; Kapoor A; Sibal A
    Indian J Pediatr; 2014 Aug; 81(8):826. PubMed ID: 24014185
    [No Abstract]   [Full Text] [Related]  

  • 52. Liver-specific F antigen in the serum of patients with liver diseases and the detection of early stage hepatocellular carcinoma.
    Mori Y; Iwama S; Mori T; Ueda S; Iesato K; Yoshida H; Wakashin Y; Wakashin M; Okuda K
    Clin Chim Acta; 1987 Apr; 164(2):127-37. PubMed ID: 2439239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Surveillance for hepatocellular carcinoma in cirrhotic patients: from official recommendations to the real life.
    Trinchet JC
    J Hepatol; 2011 Jun; 54(6):1310-1. PubMed ID: 21296113
    [No Abstract]   [Full Text] [Related]  

  • 54. Exophytic hepatocellular carcinoma, simulating a mesenchymal tumor, in a non-cirrhotic liver.
    de Siqueira GR; Guimarães MD; Franco LF; Coutinho RB; Marchiori E
    Radiol Bras; 2017; 50(1):62. PubMed ID: 28298735
    [No Abstract]   [Full Text] [Related]  

  • 55. Correction to "The adverse characteristics of hepatocellular carcinoma in the non-cirrhotic liver disproportionately disadvantage black patients".
    Cancer Med; 2024 Apr; 13(8):e7099. PubMed ID: 38656558
    [No Abstract]   [Full Text] [Related]  

  • 56. Hepatocellular carcinoma surveillance: all cirrhotic patients may not be equal.
    Mayorga C; Yopp AC; Singal AG
    Gastroenterology; 2012 Nov; 143(5):1393-1395. PubMed ID: 23010303
    [No Abstract]   [Full Text] [Related]  

  • 57. Erratum to "Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis".
    Mol Ther; 2016 Aug; 24(8):1502. PubMed ID: 27578284
    [No Abstract]   [Full Text] [Related]  

  • 58. Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients?
    Colombo M; Lleo A
    Hepatobiliary Surg Nutr; 2019 Apr; 8(2):148-150. PubMed ID: 31098364
    [No Abstract]   [Full Text] [Related]  

  • 59. Hepatocellular Carcinoma Surveillance and Treatment: A Way to Reduce Cancer-related Mortality in Cirrhotic Patients.
    Qian X; Yan X; Zhai X; Li N; Qu C; Lu F
    J Clin Transl Hepatol; 2019 Mar; 7(1):1-2. PubMed ID: 30944811
    [No Abstract]   [Full Text] [Related]  

  • 60. Investigations on the polypeptide-content of the serum.
    Godfried EG
    Biochem J; 1939 Jun; 33(6):955-9. PubMed ID: 16746997
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.